Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 397

1.

A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies.

Beeg M, Nobili A, Orsini B, Rogai F, Gilardi D, Fiorino G, Danese S, Salmona M, Garattini S, Gobbi M.

Sci Rep. 2019 Feb 14;9(1):2064. doi: 10.1038/s41598-018-37950-4.

2.

Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.

Danese S, Allez M, van Bodegraven AA, Dotan I, Gisbert JP, Hart A, Lakatos PL, Magro F, Peyrin-Biroulet L, Schreiber S, Tarabar D, Vavricka S, Halfvarson J, Vermeire S.

Dig Dis. 2019 Feb 6:1-18. doi: 10.1159/000496739. [Epub ahead of print]

3.

Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early"?

Le Berre C, Danese S, Peyrin-Biroulet L.

Dig Dis Sci. 2019 Feb 6. doi: 10.1007/s10620-019-05504-x. [Epub ahead of print] No abstract available.

PMID:
30725301
4.

Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis.

Pouillon L, Rousseau H, Busby-Venner H, De Carvalho Bittencourt M, Choukour M, Gauchotte G, Zallot C, Danese S, Baumann C, Peyrin-Biroulet L.

J Crohns Colitis. 2019 Jan 29. doi: 10.1093/ecco-jcc/jjz029. [Epub ahead of print]

PMID:
30698684
5.

Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients.

Leone D, Gilardi D, Corrò BE, Menichetti J, Vegni E, Correale C, Mariangela A, Furfaro F, Bonovas S, Peyrin-Biroulet L, Danese S, Fiorino G.

Inflamm Bowel Dis. 2019 Jan 28. doi: 10.1093/ibd/izy400. [Epub ahead of print]

PMID:
30689871
6.

Big data in IBD: a look into the future.

Olivera P, Danese S, Jay N, Natoli G, Peyrin-Biroulet L.

Nat Rev Gastroenterol Hepatol. 2019 Jan 18. doi: 10.1038/s41575-019-0102-5. [Epub ahead of print] Review.

PMID:
30659247
7.

Biosimilars of adalimumab: the upcoming challenge in IBD.

Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-Biroulet L, Danese S.

Expert Opin Biol Ther. 2019 Jan 2. doi: 10.1080/14712598.2019.1564033. [Epub ahead of print]

PMID:
30601098
8.

Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence.

Olivera P, Danese S, Pouillon L, Bonovas S, Peyrin-Biroulet L.

Dig Liver Dis. 2018 Nov 16. pii: S1590-8658(18)31221-0. doi: 10.1016/j.dld.2018.11.002. [Epub ahead of print] Review.

PMID:
30555013
9.

Role of epithelial-to-mesenchymal transition in inflammatory bowel disease.

Lovisa S, Genovese G, Danese S.

J Crohns Colitis. 2018 Dec 6. doi: 10.1093/ecco-jcc/jjy201. [Epub ahead of print]

PMID:
30520951
10.

Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study.

Vegni E, Gilardi D, Bonovas S, Corrò BE, Menichetti J, Leone D, Mariangela A, Furfaro F, Danese S, Fiorino G.

J Crohns Colitis. 2018 Dec 4. doi: 10.1093/ecco-jcc/jjy183. [Epub ahead of print]

PMID:
30517669
11.

Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience.

Pouillon L, Baumann C, Rousseau H, Choukour M, Andrianjafy C, Danese S, Peyrin-Biroulet L.

Inflamm Bowel Dis. 2018 Oct 16. doi: 10.1093/ibd/izy322. [Epub ahead of print]

PMID:
30329067
12.

Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach.

Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, Paridaens K, Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK.

Intest Res. 2018 Oct;16(4):522-528. doi: 10.5217/ir.2018.00073. Epub 2018 Oct 16.

13.

Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.

Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, Røseth A, Danese S, Feagan B, Sands BE, Ginsburg P, Dassopoulos T, Lewis J, Xu J, Wyant T.

Inflamm Bowel Dis. 2018 Oct 5. doi: 10.1093/ibd/izy304. [Epub ahead of print]

PMID:
30295811
14.

Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease.

Ungaro F, Massimino L, Furfaro F, Rimoldi V, Peyrin-Biroulet L, D'Alessio S, Danese S.

Gut Microbes. 2018 Sep 25:1-10. doi: 10.1080/19490976.2018.1511664. [Epub ahead of print]

PMID:
30252582
15.

The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study.

Sebastian S, Black C, Pugliese D, Armuzzi A, Sahnan K, Elkady SM, Katsanos KH, Christodoulou DK, Selinger C, Maconi G, Fearnhead NS, Kopylov U, Davidov Y, Bosca-Watts MM, Ellul P, Muscat M, Karmiris K, Hart AL, Danese S, Ben-Horin S, Fiorino G.

Aliment Pharmacol Ther. 2018 Nov;48(9):941-950. doi: 10.1111/apt.14969. Epub 2018 Sep 18.

PMID:
30226271
16.

The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.

Armuzzi A, Fiorino G, Variola A, Manetti N, Fries W, Orlando A, Maconi G, Bossa F, Cappello M, Biancone L, Cantoro L, Costa F, D'Incà R, Lionetti P, Principi M, Castiglione F, Annunziata ML, Di Sabatino A, Di Girolamo M, Terpin MM, Cortelezzi CC, Saibeni S, Amato A, Ardizzone S, Guidi L, Danese S, Massella A, Ventra A, Rizzuto G, Massari A, Perri F, Annese V; PROSIT Investigators .

Inflamm Bowel Dis. 2018 Aug 18. doi: 10.1093/ibd/izy264. [Epub ahead of print]

PMID:
30137352
17.

The nocebo effect: a clinical challenge in the era of biosimilars.

Pouillon L, Socha M, Demore B, Thilly N, Abitbol V, Danese S, Peyrin-Biroulet L.

Expert Rev Clin Immunol. 2018 Sep;14(9):739-749. doi: 10.1080/1744666X.2018.1512406. Epub 2018 Aug 30.

PMID:
30118338
18.

Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study.

Allocca M, Fiorino G, Bonovas S, Furfaro F, Gilardi D, Argollo M, Magnoni P, Peyrin-Biroulet L, Danese S.

J Crohns Colitis. 2018 Nov 28;12(12):1385-1391. doi: 10.1093/ecco-jcc/jjy107.

19.

Review article: treating-to-target for inflammatory bowel disease-associated anaemia.

Peyrin-Biroulet L, Lopez A, Cummings JRF, Dignass A, Detlie TE, Danese S.

Aliment Pharmacol Ther. 2018 Sep;48(6):610-617. doi: 10.1111/apt.14922. Epub 2018 Aug 1. Review.

PMID:
30069896
20.

Can IL-23 be a good target for ulcerative colitis?

Allocca M, Furfaro F, Fiorino G, Gilardi D, D'Alessio S, Danese S.

Best Pract Res Clin Gastroenterol. 2018 Feb - Apr;32-33:95-102. doi: 10.1016/j.bpg.2018.05.016. Epub 2018 May 23. Review.

PMID:
30060945

Supplemental Content

Loading ...
Support Center